Neuropsychiatric Symptoms of Alzheimer Disease, Parkinson Disease and Lewy Body Dementia: Genetic, Clinical and Therapeutic Overlaps-Advances in Geriatric Medicine and Research-CSCIED科技核心评价数据库-手机版

Neuropsychiatric Symptoms of Alzheimer Disease, Parkinson Disease and Lewy Body Dementia: Genetic, Clinical and Therapeutic Overlaps

Neuropsychiatric Symptoms of Alzheimer Disease, Parkinson Disease and Lewy Body Dementia: Genetic, Clinical and Therapeutic Overlaps

ES评分 0 浏览量：91 下载量：0

全文阅读下载引用收藏

DOI	10.20900/agmr20250013
刊名	Advances in Geriatric Medicine and Research AGMR
年，卷(期)	2025, 7(3)
作者	Leonardo Massoni*,
作者单位	Department of Psychiatry, Azienda USL Toscana Nord Ovest, Lucca 55100, Italy ;
摘要	Background: Parkinson Disease (PD) as well as other parkinsonisms such as Lewy Body Dementia (DLB), are often associated with neuropsychiatric symptoms. Hallucinations, apathy, dysphoria, anxiety, and aberrant motor behaviors are common neuropsychiatric features of both PD and DLB. The overlapping between Alzheimer disease (AD), PD, and DLB seems to be genetic, biological, clinical, and pharmacological. Methods: In this review, a literature search was carried out to analyze the correlation between genetic, molecular, neurophysiological aspects, and neuropsychiatric symptoms of the above-mentioned diseases. Results: Apolipoprotein E-4 (APOE-4), serotonin transporter gene (SLC6A4), and single nucleotide polymorphisms (SNPs) of glucocerebrosidase (GBA) are some of the main altered genes in AD, PDD and DLB. From a molecular point of view, α-synuclein and β/τ-amyloid are the main-altered proteins whose alteration has been implicated in neuropsychiatric symptoms of the diseases, while the entorhinal and parahippocampal regions, medial temporal lobes, limbic regions, and brain stem are the main impaired cerebral regions. Electrophysiological studies provided some insights into the prevalence of neuropsychiatric alterations, including visual hallucinations and poorer cognitive performance, especially in DLB, and pointed out an hypometabolism in frontal, parietal, and temporal lobes in AD. Conclusions: Overall, AD, PD, and DLB may share clinical, neurochemical, and morphological characteristics, thus leading some authors to conceive a Lewy body disease spectrum. Further studies are warranted to find out clinical and neuropathological elements helping differential diagnosis between AD, PD dementia (PDD) and DLB.
Abstract	Background: Parkinson Disease (PD) as well as other parkinsonisms such as Lewy Body Dementia (DLB), are often associated with neuropsychiatric symptoms. Hallucinations, apathy, dysphoria, anxiety, and aberrant motor behaviors are common neuropsychiatric features of both PD and DLB. The overlapping between Alzheimer disease (AD), PD, and DLB seems to be genetic, biological, clinical, and pharmacological. Methods: In this review, a literature search was carried out to analyze the correlation between genetic, molecular, neurophysiological aspects, and neuropsychiatric symptoms of the above-mentioned diseases. Results: Apolipoprotein E-4 (APOE-4), serotonin transporter gene (SLC6A4), and single nucleotide polymorphisms (SNPs) of glucocerebrosidase (GBA) are some of the main altered genes in AD, PDD and DLB. From a molecular point of view, α-synuclein and β/τ-amyloid are the main-altered proteins whose alteration has been implicated in neuropsychiatric symptoms of the diseases, while the entorhinal and parahippocampal regions, medial temporal lobes, limbic regions, and brain stem are the main impaired cerebral regions. Electrophysiological studies provided some insights into the prevalence of neuropsychiatric alterations, including visual hallucinations and poorer cognitive performance, especially in DLB, and pointed out an hypometabolism in frontal, parietal, and temporal lobes in AD. Conclusions: Overall, AD, PD, and DLB may share clinical, neurochemical, and morphological characteristics, thus leading some authors to conceive a Lewy body disease spectrum. Further studies are warranted to find out clinical and neuropathological elements helping differential diagnosis between AD, PD dementia (PDD) and DLB.
关键词	alzheimer disease; parkinson disease; lewy body dementia; cognition; depression; anxiet
KeyWord	alzheimer disease; parkinson disease; lewy body dementia; cognition; depression; anxiet
基金项目
页码	-

参考文献
相关文献

1.Capouch SD, Farlow MR, Brosch JR. A review of dementia with Lewy bodies’ impact, diagnostic criteria and treatment. Neurol Ther. 2018;7(2):249-63. doi: 10.1007/s40120-018-0104-1.

2.McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100. doi: 10.1212/WNL.0000000000004058.

3.Orad RI, Shiner T. Differentiating dementia with Lewy bodies from Alzheimer's disease and Parkinson's disease dementia: An update on imaging modalities. J Neurol. 2022;269(2):639-53. doi: 10.1007/s00415-021-10402-2.

4.Wu YC, Bogale TA, Koistinaho J, Pizzi M, Rolova T, Bellucci A. The contribution of β-amyloid, Tau and α-synuclein to blood-brain barrier damage in neurodegenerative disorders. Acta Neuropathol. 2024;147(1):39. doi: 10.1007/s00401-024-02696-z.

5.Wakasugi N, Hanakawa T. It is time to study overlapping molecular and circuit pathophysiologies in Alzheimer's and Lewy body disease spectra. Front Syst Neurosci. 2021;15:777706. doi: 10.3389/fnsys.2021.777706.

6.Colloby SJ, Watson R, Blamire AM, O'Brien JT, Taylor JP. Cortical thinning in dementia with Lewy bodies and Parkinson disease dementia. Aust N Z J Psychiatry. 2020;54(6):633-43. doi: 10.1177/0004867419885165.

7.Perovnik M, Tomše P, Jamšek J, Tang C, Eidelberg D, Trošt M. Metabolic brain pattern in dementia with Lewy bodies: Relationship to Alzheimer's disease topography. Neuroimage Clin. 2022;35:103080. doi: 10.1016/j.nicl.2022.103080.

8.Kaur B, Harvey DJ, Decarli CS, Zhang L, Sabbagh MN, Olichney JM. Extrapyramidal signs by dementia severity in Alzheimer disease and dementia with Lewy bodies. Alzheimer Dis Assoc Disord. 2013;27(3):226-32. doi: 10.1097/WAD.0b013e31826f040d.

9.Gomperts SN. Lewy body dementias: Dementia with Lewy bodies and parkinson disease dementia. Continuum (Minneap Minn). 2016;22(2):435-63. doi: 10.1212/CON.0000000000000309.

10.Goldman JG, Williams-Gray C, Barker RA, Duda JE, Galvin JE. The spectrum of cognitive impairment in Lewy body diseases. Mov Disord. 2014;29(5):608-21. doi: 10.1002/mds.25866.

11.Armstrong MJ, Moore K, Jacobson CE, Bedenfield N, Patel B, Sullivan JL. Frequency of suicidal ideation and associated clinical features in Lewy body dementia. Parkinsonism Relat Disord. 2021;90:33-7. doi: 10.1016/j.parkreldis.2021.07.029.

12.Foguem C, Manckoundia P. Lewy body disease: Clinical and pathological “Overlap Syndrome” between synucleinopathies (Parkinson Disease) and tauopathies (Alzheimer Disease). Curr Neurol Neurosci Rep. 2018;18(5):24. doi: 10.1007/s11910-018-0835-5.

13.Oliveira FF, Machado FC, Sampaio G, Marin SM, Chen ES, Smith MC, et al. Contrasts between patients with Lewy body dementia syndromes and APOE-ε3/ε3 patients with late-onset Alzheimer disease dementia. Neurologist. 2015;20(2):35-41. doi: 10.1097/NRL.0000000000000045.

14.Wyman-Chick KA, Chaudhury P, Bayram E, Abdelnour C, Matar E, Chiu SY, et al. Differentiating prodromal dementia with Lewy bodies from prodromal Alzheimer's disease: A pragmatic review for clinicians. Neurol Ther. 2024;13(3):885-906. doi: 10.1007/s40120-024-00620-x.

15.Wyman-Chick KA, Ferman TJ, Weintraub D, Armstrong MJ, Boeve BF, Bayram E, et al. Distinguishing prodromal dementia with Lewy bodies from prodromal Alzheimer disease: A longitudinal study. Neurol Clin Pract. 2025;15(1):e200380. doi: 10.1212/CPJ.0000000000200380.

16.Jellinger KA, Korczyn AD. Are dementia with Lewy bodies and Parkinson's disease dementia the same disease? BMC Med. 2018;16(1):34. doi: 10.1186/s12916-018-1016-8.

17.Tong Q, Chen L. Associations of Alzheimer's disease neuropathologic changes with clinical presentations of Parkinson's disease. J Alzheimers Dis. 2021;81(1):201-7. doi: 10.3233/JAD-210114.

18.Lindgren HS, Dunnett SB. Cognitive dysfunction and depression in Parkinson's disease: What can be learned from rodent models? Eur J Neurosci. 2012;35(12):1894-907. doi: 10.1111/j.1460-9568.2012.08162.x.

19.O'Caoimh R, Foley MJ, Timmons S, Molloy DW. Screening for cognitive impairment in movement disorders: Comparison of the montreal cognitive assessment and quick mild cognitive impairment screen in Parkinson's disease and Lewy body dementia. J Alzheimers Dis Rep. 2024;8(1):971-80. doi: 10.3233/ADR-230207.

20.Park J, Jeong E, Seomun G. The clock drawing test: A systematic review and meta-analysis of diagnostic accuracy. J Adv Nurs. 2018;74(12):2742-54. doi: 10.1111/jan.13810.

21.Nosheny RL, Yen D, Howell T, Camacho M, Moulder K, Gummadi S, et al. Evaluation of the electronic clinical dementia rating for dementia screening. JAMA Netw Open. 2023;6(9):e2333786. doi: 10.1001/jamanetworkopen.2023.33786.

22.Cummings JL. The neuropsychiatric inventory: Assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl. 6):S10-6. doi: 10.1212/wnl.48.5_suppl_6.10s.

23.Guerin JM, Copersino ML, Schretlen DJ. Clinical utility of the 15-item geriatric depression scale (GDS-15) for use with young and middle-aged adults. J Affect Disord. 2018;241:59-62. doi: 10.1016/j.jad.2018.07.038.

24.Cahn-Weiner DA, Williams K, Grace J, Tremont G, Westervelt H, Stern RA. Discrimination of dementia with lewy bodies from Alzheimer disease and Parkinson disease using the clock drawing test. Cogn Behav Neurol. 2003;16(2):85-92. doi: 10.1097/00146965-200306000-00001.

25.Chung EJ, Babulal GM, Monsell SE, Cairns NJ, Roe CM, Morris JC. Clinical features of Alzheimer disease with and without Lewy bodies. JAMA Neurol. 2015;72(7):789-96. doi: 10.1001/jamaneurol.2015.0606.

26.Real R, Martinez-Carrasco A, Reynolds RH, Lawton MA, Tan MMX, Shoai M, et al. Association between the LRP1B and APOE loci and the development of Parkinson's disease dementia. Brain. 2023;146(5):1873-87. doi: 10.1093/brain/awac414.

27.Wu LY, Real R, Martinez-Carrasco A, Chia R, Lawton MA, Shoai M, et al. Investigation of the genetic aetiology of Lewy body diseases with and without dementia. Brain Commun. 2024;6(4):fcae190. doi: 10.1093/braincomms/fcae190.

28.Gámez-Valero A, Canet-Pons J, Urbizu A, Anillo A, Santos C, Ariza A, et al. INDEL length and Haplotypes in the β-Synuclein gene: A key to differentiate dementia with Lewy bodies? J Alzheimers Dis. 2018;65(1):207-19. doi: 10.3233/JAD-180074.

29.Guerreiro R, Escott-Price V, Darwent L, Parkkinen L, Ansorge O, Hernandez DG, et al. Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiol Aging. 2016;38:214.e7-10. doi: 10.1016/j.neurobiolaging.2015.10.028.

30.Creese B, Ballard C, Aarsland D, Londos E, Sharp S, Jones E. Determining the association of the 5HTTLPR polymorphism with delusions and hallucinations in Lewy body dementias. Am J Geriatr Psychiatry. 2014;22(6):580-6. doi: 10.1016/j.jagp.2012.11.001.

31.Quaranta D, Bizzarro A, Marra C, Vita MG, Seripa D, Pilotto A, et al. Psychotic symptoms in Alzheimer's disease and 5-HTTLPR polymorphism of the serotonin transporter gene: Evidence for an association. J Alzheimers Dis. 2009;16(1):173-80. doi: 10.3233/JAD-2009-0950.

32.Sweet RA, Pollock BG, Sukonick DL, Mulsant BH, Rosen J, Klunk WE, et al. The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease. Int Psychogeriatr. 2001;13(4):401-9. doi: 10.1017/s1041610200007827.

33.Blauwendraat C, Reed X, Krohn L, Heilbron K, Bandres-Ciga S, Tan M, et al. Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. Brain. 2020;143(1):234-48. doi: 10.1093/brain/awz350.

34.Dai DL, Tropea TF, Robinson JL, Suh E, Hurtig H, Weintraub D, et al. ADNC-RS, a clinical-genetic risk score, predicts Alzheimer's pathology in autopsy-confirmed Parkinson's disease and Dementia with Lewy bodies. Acta Neuropathol. 2020;140(4):449-61. doi: 10.1007/s00401-020-02199-7.

35.Fisher DW, Tulloch J, Yu CE, Tsuang D. A preliminary comparison of the methylome and transcriptome from the prefrontal cortex across Alzheimer's disease and Lewy body dementia. J Alzheimers Dis Rep. 2023;7(1):279-97. doi: 10.3233/ADR220114.

36.Majumdar A, Patel P, Pasaniuc B, Ophoff RA. A summary-statistics-based approach to examine the role of serotonin transporter promoter tandem repeat polymorphism in psychiatric phenotypes. Eur J Hum Genet. 2022;30(5):547-54. doi: 10.1038/s41431-021-00996-6.

37.Griffin WS, Liu L, Li Y, Mrak RE, Barger SW. Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflammation. 2006;3:5. doi: 10.1186/1742-2094-3-5.

38.Mrak RE, Griffin WS. Dementia with Lewy bodies: Definition, diagnosis, and pathogenic relationship to Alzheimer's disease. Neuropsychiatr Dis Treat. 2007;3(5):619-25.

39.Winslow AR, Moussaud S, Zhu L, Post KL, Dickson DW, Berezovska O, et al. Convergence of pathology in dementia with Lewy bodies and Alzheimer's disease: A role for the novel interaction of alpha-synuclein and presenilin 1 in disease. Brain. 2014;137(Pt 7):1958-70. doi: 10.1093/brain/awu119.

40.Matsuoka T, Narumoto J, Morii-Kitani F, Niwa F, Mizuno T, Abe M, et al. Parkinson's and Alzheimer's disease dimensional neuroimaging initiative. Contribution of amyloid and putative Lewy body pathologies in neuropsychiatric symptoms. Int J Geriatr Psychiatry. 2023;38(9):e5993. doi: 10.1002/gps.5993.

41.Couture V, Carmel JF, Rousseau K, Létourneau G, Clerc D, Huot P, et al. Sex differences in neuropsychiatric symptoms in alpha-synucleinopathies: A systematic review and meta-analysis. Mov Disord Clin Pract. 2024;11(11):1335-44. doi: 10.1002/mdc3.14227.

42.Bougea A, Stefanis L, Paraskevas GP, Emmanouilidou E, Efthymiopoulou E, Vekrelis K, et al. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease. J Neurol. 2018;265(10):2295-301. doi: 10.1007/s00415-018-8992-7.

43.Kao AW, Racine CA, Quitania LC, Kramer JH, Christine CW, Miller BL. Cognitive and neuropsychiatric profile of the synucleinopathies: Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. Alzheimer Dis Assoc Disord. 2009;23(4):365-70. doi: 10.1097/WAD.0b013e3181b5065d.

44.Braak H, Del Tredici K. Invited article: Nervous system pathology in sporadic Parkinson disease. Neurology. 2008;70(20):1916-25. doi: 10.1212/01.wnl.0000312279.49272.9f.

45.Shen H, Yu Y, Wang J, Nie Y, Tang Y, Qu M. Plasma lipidomic signatures of dementia with Lewy bodies revealed by machine learning, and compared to alzheimer's disease. Alzheimers Res Ther. 2024;16(1):226. doi: 10.1186/s13195-024-01585-7.

46.Shantaraman A, Dammer EB, Ugochukwu O, Duong DM, Yin L, Carter EK, et al. Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer's disease. Mol Neurodegener. 2024;19(1):60. doi: 10.1186/s13024-024-00749-1.

47.Ruffmann C, Calboli FC, Bravi I, Gveric D, Curry LK, de Smith A, et al. Cortical Lewy bodies and Aβ burden are associated with prevalence and timing of dementia in Lewy body diseases. Neuropathol Appl Neurobiol. 2016;42(5):436-50. doi: 10.1111/nan.12294.

48.Hirschberg Y, Valle-Tamayo N, Dols-Icardo O, Engelborghs S, Buelens B, Vandenbroucke RE, et al. Proteomic comparison between non-purified cerebrospinal fluid and cerebrospinal fluid-derived extracellular vesicles from patients with Alzheimer's, Parkinson's and Lewy body dementia. J Extracell Vesicles. 2023;12(12):e12383. doi: 10.1002/jev2.12383.

49.Kaerst L, Kuhlmann A, Wedekind D, Stoeck K, Lange P, Zerr I. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease. J Alzheimers Dis. 2014;38(1):63-73. doi: 10.3233/JAD-130995.

50.Aerts MB, Esselink RA, Claassen JA, Abdo WF, Bloem BR, Verbeek MM. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease. J Alzheimers Dis. 2011;27(2):377-84. doi: 10.3233/JAD-2011-110482.

51.Geng C, Tan L, Chen C. Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias. Brain Res. 2024;1833:148881. doi: 10.1016/j.brainres.2024.148881.

52.Jellinger KA. Significance of brain lesions in Parkinson disease dementia and Lewy body dementia. Front Neurol Neurosci. 2009;24:114-25. doi: 10.1159/000197890.

53.Hall H, Reyes S, Landeck N, Bye C, Leanza G, Double K, et al. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. Brain. 2014;137(Pt 9):2493-508. doi: 10.1093/brain/awu193.

54.Colloby SJ, McKeith IG, Burn DJ, Wyper DJ, O'Brien JT, Taylor JP. Cholinergic and perfusion brain networks in Parkinson disease dementia. Neurology. 2016;87(2):178-85. doi: 10.1212/WNL.0000000000002839.

55.Watson R, Colloby SJ, Blamire AM, O’Brien JT. Assessment of regional gray matter loss in dementia with Lewy bodies: A surface-based MRI analysis. Am J Geriatr Psychiatry. 2015;23(1):38-46. doi: 10.1016/j.jagp.2014.07.005.

56.Lebedev AV, Westman E, Beyer MK, Kramberger MG, Aguilar C, Pirtosek Z, et al. Multivariate classification of patients with Alzheimer's and dementia with Lewy bodies using high-dimensional cortical thickness measurements: an MRI surface-based morphometric study. J Neurol. 2013;260(4):1104-15. doi: 10.1007/s00415-012-6768-z.

57.Ye R, Touroutoglou A, Brickhouse M, Katz S, Growdon JH, Johnson KA, et al. Topography of cortical thinning in the Lewy body diseases. Neuroimage Clin. 2020;26:102196. doi: 10.1016/j.nicl.2020.102196.

58.Adamowicz DH, Roy S, Salmon DP, Galasko DR, Hansen LA, Masliah E, et al. Hippocampal α-Synuclein in dementia with Lewy Bodies contributes to memory impairment and is consistent with spread of pathology. J Neurosci. 2017;37(7):1675-84. doi: 10.1523/JNEUROSCI.3047-16.2016.

59.Yoo HS, Lee EC, Chung SJ, Lee YH, Lee SG, Yun M, et al. Effects of Alzheimer's disease and Lewy body disease on subcortical atrophy. Eur J Neurol. 2020;27(2):318-26. doi: 10.1111/ene.14080.

60.Cousins DA, Burton EJ, Burn D, Gholkar A, McKeith IG, O'Brien JT. Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer's disease: An MRI study. Neurology. 2003;61(9):1191-5. doi: 10.1212/01.wnl.0000091889.20347.30.

61.Müller SJ, Khadhraoui E, Hansen N, Jamous A, Langer P, Wiltfang J, et al. Brainstem atrophy in dementia with Lewy bodies compared with progressive supranuclear palsy and Parkinson's disease on MRI. BMC Neurol. 2023;23(1):114. doi: 10.1186/s12883-023-03151-4.

62.Zhou H, Jiang J, Wu P, Guo Q, Zuo C. Disrupted network topology in patients with Lewy bodies dementia compared to Alzheimer's disease, Parkinson disease dementia and Health Control. Annu Int Conf IEEE Eng Med Biol Soc. 2018;2018:1899-902. doi: 10.1109/EMBC.2018.8512637.

63.Hansen D, Ling H, Lashley T, Foley JA, Strand C, Eid TM, et al. Novel clinicopathological characteristics differentiate dementia with Lewy bodies from Parkinson's disease dementia. Neuropathol Appl Neurobiol. 2021;47(1):143-56. doi: 10.1111/nan.12648.

64.Peraza LR, Colloby SJ, Deboys L, O'Brien JT, Kaiser M, Taylor JP. Regional functional synchronizations in dementia with Lewy bodies and Alzheimer's disease. Int Psychogeriatr. 2016;28(7):1143-51. doi: 10.1017/S1041610216000429.

65.Donaghy PC, Carrarini C, Ferreira D, Habich A, Aarsland D, Babiloni C, et al. Research diagnostic criteria for mild cognitive impairment with Lewy bodies: A systematic review and meta-analysis. Alzheimers Dement. 2023;19(7):3186-202. doi: 10.1002/alz.13105.

66.Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain. 2008;131(Pt 3):690-705. doi: 10.1093/brain/awm322.

67.Yong SW, Yoon JK, An YS, Lee PH. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. Eur J Neurol. 2007;14(12):1357-62. doi: 10.1111/j.1468-1331.2007.01977.x.

68.Granert O, Drzezga AE, Boecker H, Perneczky R, Kurz A, Götz J, et al. Metabolic topology of neurodegenerative disorders: Influence of cognitive and motor deficits. J Nucl Med. 2015;56(12):1916-21. doi: 10.2967/jnumed.115.156067.

69.Perovnik M, Tomše P, Jamšek J, Tang C, Eidelberg D, Trošt M. Metabolic brain pattern in dementia with Lewy bodies: Relationship to Alzheimer's disease topography. Neuroimage Clin. 2022;35:103080. doi: 10.1016/j.nicl.2022.103080.

70.McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100. doi: 10.1212/WNL.0000000000004058.

71.Peraza LR, Colloby SJ, Firbank MJ, Greasy GS, McKeith IG, Kaiser M, et al. Resting state in Parkinson's disease dementia and dementia with Lewy bodies: commonalities and differences. Int J Geriatr Psychiatry. 2015;30(11):1135-46. doi: 10.1002/gps.4342.

72.Joki H, Higashiyama Y, Nakae Y, Kugimoto C, Doi H, Kimura K, et al. White matter hyperintensities on MRI in dementia with Lewy bodies, Parkinson's disease with dementia, and Alzheimer's disease. J Neurol Sci. 2018;385:99-104. doi: 10.1016/j.jns.2017.12.018.

73.Connolly BS, Fox SH. Drug treatments for the neuropsychiatric complications of Parkinson's disease. Expert Rev Neurother. 2012;12(12):1439-49. doi: 10.1586/ern.12.142.

74.Sobow T. Parkinson's disease-related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: A case series. Neurol Neurochir Pol. 2007;41(3):276-9.

75.Mühlbauer V, Möhler R, Dichter MN, Zuidema SU, Köpke S, Luijendijk HJ. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev. 2021;12(12):CD013304. doi: 10.1002/14651858.CD013304.pub2.

76.Elefante C, Brancati GE, Torrigiani S, Amadori S, Ricciardulli S, Pistolesi G, et al. Bipolar disorder and manic-like symptoms in Alzheimer's, vascular and frontotemporal dementia: A systematic review. Curr Neuropharmacol. 2023;21(12):2516-42. doi: 10.2174/1570159X20666220706110157.

77.Devanand DP, Pelton GH, D'Antonio K, Strickler JG, Kreisl WC, Noble J, et al. Low-dose Lithium treatment for agitation and psychosis in Alzheimer disease and frontotemporal dementia: A case series. Alzheimer Dis Assoc Disord. 2017;31(1):73-5. doi: 10.1097/WAD.0000000000000161.

78.Burns A, O'Brien J, BAP Dementia Consensus group, Auriacombe S, Ballard C, Broich K, et al. Clinical practice with anti-dementia drugs: A consensus statement from British Association for Psychopharmacology. J Psychopharmacol. 2006;20(6):732-55. doi: 10.1177/0269881106068299.

79.Bergström AL, Kallunki P, Fog K. Development of passive immunotherapies for synucleinopathies. Mov Disord. 2016;31(2):203-13. doi: 10.1002/mds.26481.

80.Schneeberger A, Tierney L, Mandler M. Active immunization therapies for Parkinson's disease and multiple system atrophy. Mov Disord. 2016;31(2):214-24. doi: 10.1002/mds.26377.

81.Cummings J, Blennow K, Johnson K, Keeley M, Bateman RJ, Molinuevo JL, et al. Anti-Tau trials for Alzheimer's disease: A report from the EU/US/CTAD task force. J Prev Alzheimers Dis. 2019;6(3):157-63. doi: 10.14283/jpad.2019.14.

82.Angioni D, Middleton L, Bateman R, Aisen P, Boxer A, Sha S, et al. Challenges and opportunities for novel combination therapies in Alzheimer's disease: A report from the EU/US CTAD task force. J Prev Alzheimers Dis. 2025:100163. doi: 10.1016/j.tjpad.2025.100163.

83.Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA. 2005;102(19):6990-5. doi: 10.1073/pnas.0500466102.

84.Forlenza OV, Radanovic M, Talib LL, Gattaz WF. Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: Randomised clinical trial. Br J Psychiatry. 2019;215(5):668-74. doi: 10.1192/bjp.2019.76.

85.Hermida AP, Sterina E, Schwab PP, Browning CM, Chapman HM, Marques Pinheiro AP, et al. Ultrabrief right unilateral electroconvulsive therapy for the treatment of the neuropsychiatric symptoms of dementia with Lewy bodies. J ECT. 2022;38(1):39-44. doi: 10.1097/YCT.0000000000000809.

86.Ramesh V, Sharma A, Sharma V, Somani A. Treatment of catatonia in Parkinson's disease with electroconvulsive therapy. Ann Indian Acad Neurol. 2019;22(4):501-3. doi: 10.4103/aian.AIAN_308_18.

87.Elefante C, Brancati GE, Tripodi B, Torrigiani S, Lattanzi L, Medda P, et al. Catatonia in two women with Parkinson’s disease treated with electroconvulsive therapy. Explor Neuroprot Ther. 2022;2:256-63. doi: 10.37349/ent.2022.00032.

88.Wightman DP, Savage JE, Tissink E, Romero C, Jansen IE, Posthuma D. The genetic overlap between Alzheimer's disease, amyotrophic lateral sclerosis, Lewy body dementia, and Parkinson's disease. Neurobiol Aging. 2023;127:99-112. doi: 10.1016/j.neurobiolaging.2023.03.004.

89.Olney KC, Rabichow BE, Wojtas AM, DeTure M, McLean PJ, Dickson DW, et al. Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease. Brain. 2025;148(1):69-88. doi: 10.1093/brain/awae202.

90.Sengupta U, Kayed R. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Prog Neurobiol. 2022;214:102270. doi: 10.1016/j.pneurobio.2022.102270.

91.Jellinger KA. Are there morphological differences between Parkinson's disease-dementia and dementia with Lewy bodies? Parkinsonism Relat Disord. 2022;100:24-32. doi: 10.1016/j.parkreldis.2022.05.024.

92.Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: Number needed to harm. JAMA Psychiatry. 2015;72(5):438-45. doi: 10.1001/jamapsychiatry.2014.3018.

93.Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15(1):15-28. doi: 10.2165/00002512-199915010-00002.

94.Ramm RM, Lerner ZI, Levy-Meeks GS, Burke RV, Raven MC, Song A, et al. A case report of treatment-resistant agitation in dementia with Lewy bodies: Medical marijuana as an alternative to antipsychotics. J Palliat Med. 2023;26(5):737-40. doi: 10.1089/jpm.2022.0343.

95.Horn S, Richardson H, Xie SX, Weintraub D, Dahodwala N. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies. Parkinsonism Relat Disord. 2019;69:119-24. doi: 10.1016/j.parkreldis.2019.11.009.

引用本文

Leonardo Massoni*. Neuropsychiatric Symptoms of Alzheimer Disease, Parkinson Disease and Lewy Body Dementia: Genetic, Clinical and Therapeutic Overlaps [J]. Advances in Geriatric Medicine and Research. 2025; 7; (3). - .

文献评论

相关学者

相关机构